reMYND now offers Long Term Potentiation (LTP) measurements to allow clients to assess the effect of their experimental Alzheimer treatment.
LTP measurements available through reMYND
reMYND’s novel diabetes treatment prevents – and even reverses – disease progression in pre-clinical diabetes models
Press release | reMYND NV announced today that its experimental diabetes drug ReS39 has demonstrated a strong disease modifying effect in mice, in which the insulin producing capacity of β-cells is preserved - possibly even restored– in a durable way through a novel mechanism of action.
Tulips for Parkinson’s
Press release | For 2014, reMYND has dedicated the proceeds of its new year cards to the Vlaamse Parkinson Liga as part of StuBru’s Music-for-Life action.
Tau.P301S model available at reMYND’s CRO for efficacy testing of Alzheimer treatments
Over the last years, more and more tau-treatments are being assessed in mouse models for their potential to treat Alzheimer’s disease. One of the key challenges with many of the tau mouse models is the need for large numbers of animals due to their intrinsic variability.
reMYND’s Tau.P301L mice used to demonstrate efficacy of antibody treatment on behaviour and pathological read-outs
In the last several years, Tau-directed therapies have gained more interest as a strategy for treating Alzheimer’s Disease.